Caplin Point Laboratories Share News - Latest Updates, Live News & More

Latest news about Caplin Point Laboratories

Caplin Point Laboratories Shareholders Approve Appointment of Four New Directors Through Postal Ballot 2 hrs ago Today

Caplin Point Laboratories shareholders approved four new director appointments through postal ballot concluded January 31, 2026. Mr. Ashok Partheeban and Mr. Vivek Partheeban were appointed as Vice-Chairmen (Non-executive Non-Independent) effective November 5, 2025. Dr. K C John joined as Independent Director for five years from November 5, 2025, while Mrs. Susan Mathew was appointed Independent Director for five years from January 31, 2026. Mrs. Susan Mathew brings 36 years of distinguished IAS service including senior roles as Tamil Nadu Electricity Board Chairman and Additional Chief Secretary.

Caplin Point Laboratories Schedules Q3FY26 Earnings Conference Call for February 05, 2026 5 days ago

Caplin Steriles Receives USFDA Approval for Methylprednisolone Acetate Injectable Suspension 7 days ago

Caplin Point acquires 10 approved ANDAs to strengthen US injectables portfolio Jan 01, 2026

Caplin Point Lab: Company Completes INVIMA-Colombia Inspection At Puducherry Injectable Facility Dec 12, 2025

More news about Caplin Point Laboratories

08Dec 25

Caplin Point Laboratories' Subsidiary Secures USFDA Approvals for Generic Injections

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received USFDA approvals for two injectable products. The company obtained final approval for Linezolid Injection 600mg/300ml, with an estimated US market of $23.00 million by October 2025. Additionally, Caplin Steriles secured approval for Acetaminophen Injection (1000 MG/100 ML), projecting US sales of $86.00 million by October 2025. These approvals validate the company's R&D capabilities and open up new opportunities in the US pharmaceutical market.

05Nov 25

Caplin Point Laboratories Reports Strong Q2 FY26 Performance with 22.5% PAT Growth

Caplin Point Laboratories announced robust Q2 FY26 results with revenue from operations at ₹534.04 crores, up 10.5% YoY. Total revenue increased by 12% to ₹564.41 crores. Profit After Tax grew significantly by 22.5% to ₹160.23 crores. EBITDA rose 18.3% to ₹219.54 crores. The company's US market revenue grew by 27% to ₹221 crores in H1 FY26. Caplin Point maintains a strong financial position with ₹1,334 crores in free cash reserves. The company has expanded its presence in regulated markets with 42 ANDA approvals and is pursuing backward integration for 60% of all ANDAs. New board appointments include Mr. Ashok Partheeban and Mr. Vivek Partheeban as Additional Directors and Vice-Chairmen.

23Oct 25

Caplin Point Laboratories Secures USFDA Approval and Expands Portfolio with $121 Million ANDA Acquisitions

Caplin Point Laboratories has strengthened its U.S. market position through two major developments. Its subsidiary, Caplin Steriles Limited, received USFDA approval for Nicardipine Hydrochloride Injection, a product with a U.S. market size of approximately $68 million. Additionally, the company acquired four ANDA products valued at $121 million, including treatments for hereditary angioedema, secondary hyperparathyroidism, bacterial eye infections, and anesthesia. These products are set to be introduced in the U.S. and other markets in 2026. Caplin Steriles has filed 52 ANDAs in the U.S. and received 42 approvals, with plans to file over 40 more products in the next four years.

03Sept 25

Caplin Steriles Secures USFDA Approval for Generic Milrinone Lactate Injection

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received final USFDA approval for its ANDA for Milrinone Lactate in 5% Dextrose Injection. The product, available in 20 mg/100 mL and 40 mg/200 mL strengths, is a generic equivalent of PRIMACOR. The US market for this injection generated approximately $11.00 million in sales for the 12-month period ending July 2025. Milrinone is used for short-term intravenous treatment of acute decompensated heart failure. Caplin Steriles has filed 51 ANDAs in the USA, with 40 approvals so far, and plans to file over 40 more products in the next four years.

07Aug 25

Caplin Point Laboratories Reports Robust Q1 FY26 Performance with 20.7% Growth in Net Profit

Caplin Point Laboratories announced strong Q1 FY26 results with consolidated revenue up 11.7% to ₹533.40 crores. Net profit increased by 20.7% to ₹150.80 crores, while EBITDA grew 17.9% to ₹200.90 crores. The company expanded its presence in Latin America, won significant tenders, and showed growth in US operations. Strategic initiatives include expanding manufacturing capabilities and exploring US acquisitions. The company maintains a strong financial position with ₹1,237.00 crores in free cash reserves. A final dividend of ₹3.00 per share was recommended, bringing the total FY 2024-25 dividend to ₹6.00 per share.

04Jun 25

Caplin Point Laboratories: Subsidiary to Acquire Mexican Pharma Company Triwin Pharma

Caplin Point Laboratories' subsidiary, Caplin Point Far East Ltd, has signed an agreement to acquire 100% stake in Triwin Pharma S.A. de C.V., a Mexican pharmaceutical company. This acquisition aims to establish a local presence in Mexico for tender sales, direct sales, marketing, and distribution of Caplin Point's products. The deal is expected to be completed within 30 days, subject to closing conditions and regulatory approvals.

15May 25

Caplin Point Laboratories: Q4 Profit Up 17%, Declares ₹3 Dividend

Caplin Point Laboratories announced strong Q4 FY2024 results with a 17.30% year-over-year increase in consolidated net profit to ₹142.60 crore. Revenue grew by 11.00% to ₹503.00 crore, while EBITDA margin expanded to 33.50%. The company declared an interim dividend of ₹3.00 per share for FY25 and projects 13-14% topline growth for FY26 with EBITDA margins expected between 32-34%.

14May 25

Caplin Point Laboratories' Subsidiary Secures FDA Approval for Haloperidol Decanoate Injection

A subsidiary of Caplin Point Laboratories has received USFDA approval for Haloperidol Decanoate Injection, an antipsychotic medication used to treat schizophrenia and other mental health disorders. This approval allows the company to market and distribute the product in the United States, potentially boosting revenue and market share. The development strengthens Caplin Point's position in the global pharmaceutical industry and provides access to the lucrative US healthcare market.

23Apr 25

Caplin Point's Subsidiary Secures USFDA Approval for Vital Injectable Drug

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has received USFDA approval for its generic Phytonadione Injectable Emulsion USP. This 10 mg/mL single-dose vial formulation treats Vitamin K deficiency. The US market for this product was valued at $18.50 million for the year ending February 2025. This approval marks Caplin Steriles' 35th USFDA approval out of 47 ANDA filings. The company plans to file over 40 more products in the next four years and is expanding globally.

03Apr 25

Caplin Point Laboratories Expands into Chilean Pharmaceutical Market through Strategic Acquisition

Caplin Point Laboratories' subsidiary, Caplin Point Far East Limited, has acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company in Chile. The acquisition, completed on April 1, 2025, involved purchasing all 3,000 shares at face value, totaling approximately USD 3,000. This move transforms Neoethicals Chile SpA into a wholly-owned subsidiary, enhancing Caplin Point's direct presence in the Chilean market for sales, marketing, and distribution of its products.

02Apr 25

Caplin Point Laboratories Expands Footprint in Chile with Strategic Acquisition

Caplin Point Laboratories' subsidiary, Caplin Point Far East Limited, has acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company in Chile. The acquisition, completed on April 1, 2025, involved purchasing 3,000 shares at 1,000 Chilean Pesos per share, totaling approximately USD 3,000. Neoethicals Chile SpA, incorporated in 2015, has shown significant growth with a turnover of 278,565,412 Chilean Pesos (USD 295,222) in 2024. This strategic move aims to establish a direct sales and distribution channel in Chile, strengthening Caplin Point's position in the South American pharmaceutical market.

27Feb 25

Caplin Steriles Secures FDA Approval for Glaucoma Treatment, Tapping into $242 Million Market

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received USFDA approval for its ANDA for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. The approved eye drops, equivalent to COMBIGAN, are indicated for reducing elevated intraocular pressure in glaucoma or ocular hypertension patients. The product had US sales of approximately $242 million for the 12-month period ending December 2022. Caplin Steriles has developed 46 ANDAs, secured 34 approvals, and plans to expand its portfolio with over 40 products in the next four years.